Browsing restrictions can be lifted for a fee.
Pegavision Corporation manufactures and sells medical devices, and optical and precision instruments in Taiwan. The company was incorporated in 2009 and is based in Taoyuan City, Taiwan. Pegavision Corporation is a subsidiary of Pegatron Corp.
6491
晶碩
-2.45%
(-0.02)
The most recent financial report for 晶碩 (6491) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6491's short-term business performance and financial health. For the latest updates on 6491's earnings releases, visit this page regularly.
According to historical valuation range analysis, 晶碩 (6491)'s current price-to-earnings (P/E) ratio is 11.06, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 晶碩 (6491) reported an Operating Profit of 516.77M with an Operating Margin of 26.77% this period, representing a growth of 6.41% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 晶碩 (6491) announced revenue of 1.93B, with a Year-Over-Year growth rate of 7.56%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 晶碩 (6491) held Total Cash and Cash Equivalents of 1.71B, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 晶碩 (6491) achieved the “three margins increasing” benchmark, with a gross margin of 52.6%%, operating margin of 26.77%%, and net margin of 22.48%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6491's profit trajectory and future growth potential.
According to the past four quarterly reports, 晶碩 (6491)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 5.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
晶碩 (6491)'s Free Cash Flow (FCF) for the period is 113.27M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 392.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.